CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 467 enrolled
Drug / intervention
voriconazole (Vfend) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01480219
NCT01480219N/ACompleted
CompareCT.gov

Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart/Lung Transplant Patients, 2002-2009

Pfizer·observational·Posted Nov 28, 2011·Updated Mar 11, 2013

In Brief

An observational study evaluating voriconazole (Vfend) and no voriconazole (Vfend) for Non-Melanoma Skin Carcinoma. Completed, enrolled 467 participants.

Detailed Summary

The primary objective of the study is to assess the relationship (both crude and adjusted) between voriconazole utilization and the development of non-melanoma skin cancer among adult patients who received a lung or heart/lung transplant and were continuously enrolled in a large U.S. commercial health plan.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Melanoma Skin Carcinoma
Countries--
CollaboratorsUniversity of Southern California

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 28, 2011
Enrollment StartAug 1, 2011
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 14.6 years ago

Interventions

voriconazole (Vfend)drug

Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.

no voriconazole (Vfend)other

Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.